Quick Answer
Apimeds Pharmaceuticals US, Inc. reported Net Income of -$1.39 million for fiscal year 2024.
Apimeds Pharmaceuticals US, Inc. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net Income | -$1.39M -78.7% |
-$777.7K | — |
| Diluted EPS | -$0.18 -5.9% |
-$0.17 | — |
| Total Assets | $13.1K -96.9% |
$422.1K | — |
| Cash and Equivalents | $3.5K -99.2% |
$410.5K | — |
| Stockholders Equity | -$1.36M -4361.6% |
$31.9K +104.5% |
-$713.6K |
| R&D Expense | — | $98.5K | — |
| Operating Income | -$1.28M -70.6% |
-$747.4K | — |
| Shares Outstanding | 7.90M +0.0% |
7.90M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$1.78M | -435.7% | +33.1% |
| Diluted EPS | September 30, 2025 | -$0.14 | -250.0% | +46.2% |
| Total Assets | September 30, 2025 | $9.25M | — | -12.3% |
| Cash and Equivalents | September 30, 2025 | $6.99M | — | -20.0% |
| Stockholders Equity | September 30, 2025 | $8.16M | +879.8% | -16.2% |
| R&D Expense | September 30, 2025 | $619.7K | — | -4.9% |
| Operating Income | September 30, 2025 | -$1.84M | -514.7% | +30.8% |
| Shares Outstanding | September 30, 2025 | 12.58M | — | +0.0% |
- Apimeds Pharmaceuticals US, Inc. reported Net Income of -$1.39 million for fiscal year 2024.
- Apimeds Pharmaceuticals US, Inc. showed a decrease of -78.7% in Net Income compared to the prior fiscal year.
- Apimeds Pharmaceuticals US, Inc. reported Diluted EPS of $0.18 per share (loss) for fiscal year 2024.
- Apimeds Pharmaceuticals US, Inc. showed a decrease of -5.9% in Diluted EPS compared to the prior fiscal year.
- Apimeds Pharmaceuticals US, Inc. reported Total Assets of $13.1 thousand for fiscal year 2024.
- Apimeds Pharmaceuticals US, Inc. showed a decrease of -96.9% in Total Assets compared to the prior fiscal year.
- Apimeds Pharmaceuticals US, Inc. reported Cash and Equivalents of $3.5 thousand for fiscal year 2024.
- Apimeds Pharmaceuticals US, Inc. showed a decrease of -99.2% in Cash and Equivalents compared to the prior fiscal year.
- Apimeds Pharmaceuticals US, Inc. reported Stockholders Equity of -$1.36 million for fiscal year 2024.
- Apimeds Pharmaceuticals US, Inc. showed a decrease of -4361.6% in Stockholders Equity compared to the prior fiscal year.
- Apimeds Pharmaceuticals US, Inc. reported R&D Expense of $98.5 thousand for fiscal year 2023.
- Apimeds Pharmaceuticals US, Inc. reported Operating Income of -$1.28 million for fiscal year 2024.
- Apimeds Pharmaceuticals US, Inc. showed a decrease of -70.6% in Operating Income compared to the prior fiscal year.
- Apimeds Pharmaceuticals US, Inc. reported Shares Outstanding of 7.90 million shares for fiscal year 2024.
- Apimeds Pharmaceuticals US, Inc. showed an increase of +0.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: